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Biliary tract cancer, encompassing tumors of the gallbladder, ex-
trahepatic bile ducts and ampulla of Vater, is a rare but highly
fatal malignancy. Obesity and gallstones, both related to insulin
resistance, are linked to an elevated risk of biliary cancer. The
peroxisome proliferator-activated receptors (PPARs) and the ret-
inoid X receptors (RXRs), expressed in adipose tissue, play a key
role in the regulation of obesity-related insulin sensitivity, thus
genetic variants of these two receptor genes may be related to
biliary cancer and stones. We examined the associations of seven
single-nucleotide polymorphisms in the PPAR-g, PPAR-d, RXR-a,
RXR-b and INS genes with biliary cancer and stones in a
population-based case–control study in Shanghai, China. We in-
cluded 237 gallbladder, 127 extrahepatic bile duct and 47 ampulla
of Vater cancer cases, 895 stone cases and 786 population controls.
Relative to individuals with the RXR-b C51T (rs2076310) CC
genotype, those having the TT genotype had a 1.6-fold risk for
bile duct cancer [odds ratio (OR) 5 1.67; 95% conﬁdence inter-
val (CI) 5 0.99–2.84], with a morepronouncedassociation among
men (OR 5 2.30; 95% CI 5 1.14–4.65; P interaction 5 0.07).
This marker was also associated with a higher risk of gallstones
among subjects with a higher body mass index (BMI) (‡23 kg/m2)
(OR 5 1.80; 95% CI 5 1.09–2.94), although the interaction with
BMI was not statistically signiﬁcant (P interaction 5 0.28). No
association was found between other variants and biliary cancers
and stones. Results from this population-based study suggest
that certain genetic variants involved in the regulation of
obesity-related insulin sensitivity may increase susceptibility to
bile duct cancer and gallstones.
Introduction
Cancer of the biliary tract, comprising tumors of the gallbladder,
extrahepatic bile ducts and ampulla of Vater, is a rare but often fatal
cancer with incidence rates ranging from 1 to 10 per 100 000 globally
(1). The prognosis of the disease is poor; most patients do not survive
longer than a year, and 5-year relative survival rates range from 10 to
20% (2). Large geographic variations and ethnic differences in in-
cidence have been reported (1), with Europeans having a high risk
of gallbladder cancer and Asians having a high risk of bile duct
cancer. Geographic and ethnic variation in rates suggest a possible
role of genetic susceptibility, whereas the recent increase in biliary
tract cancer in certain Eastern populations, including Shanghai, China
(2,3) also suggests the importance of environmental factors. Apart
from a close association between gallstones and gallbladder cancer,
putative risk factors such as obesity (3,4), diabetes (5,6), smoking (7)
alcohol consumption (8) and reproductive and hormonal factors (1,9),
have been implicated.
Obesity has been linked to gallbladder cancer, particularly in
women (10,11), and extrahepatic bile duct cancer in both men and
women (12). Although the risk of biliary tract cancers associated with
obesity may reﬂect the well-established association with antecedent
gallstones, the mechanism underlying obesity and biliary tract cancer
is unclear. Because obesity often leads to insulin resistance, we spec-
ulate that insulin resistance may mediate the risk of biliary tract
cancer through obesity.
One of the potential biological pathways mediating obesity and
insulin resistance in biliary tract cancer pathogenesis is through the
functional heterodimers of peroxisome proliferator-activated recep-
tors (PPARs) and retinoid X receptors (RXRs) (13,14). The PPARs
are members of a nuclear hormone receptor subfamily of transcription
factors that is expressed predominantly in the adipose tissue and the
immune system and has been implicated to play a role in the regula-
tion of obesity-related insulin sensitivity (15). PPARs form hetero-
dimers with RXRs, which regulate the transcription of various genes
implicated in promoting insulin sensitization in the context of obesity
and the control of lipid metabolism, carcinogenesis and inﬂammation
(15,16). Polymorphisms in the PPAR gene have been associated with
insulin resistance (17), obesity (17,18) and colorectal cancer (19,20);
variants of RXR have been linked to hyperlipidemia (21) and renal cell
carcinoma (22) and INS gene variants have been associated with
prostate cancer (23). Despite the associations of diabetes and obesity
with gallstones and biliary tract cancers, the role of insulin-related
genes has not been examined in biliary tract stones or cancer. In this
report, we examined the associations of polymorphisms in the PPAR,
RXR and INS genes with biliary tract cancer and stone risk in a
population-based case–control study in Shanghai, China.
Materials and methods
Study population
The study protocol was approved by the Institutional Review Boards of the
USA National Cancer Institute and Shanghai Cancer Institute. All participants
provided written informed consent. Details of the study have been reported
elsewhere (24–26). The Shanghai biliary tract cancer study is a population-
based case–control study that recruited permanent Shanghai residents between
the ages of 40 and 74 years who were newly diagnosed with primary biliary
cancer (International Classiﬁcation of Diseases 9, code 156) between June
1997 and May 2001 through a rapid reporting system established by the
Shanghai Cancer Institute and 42 collaborating hospitals in urban Shanghai.
This reporting system captured .95% of biliary tract cancer patients diag-
nosed in Shanghai during this study period. A total of 2092 permanent resi-
dents of urban Shanghai, including 627 biliary tract cancer cases (368
gallbladder, 191 bile duct and 68 ampulla of Vater), 1037 biliary stone cases
(774 gallbladder and 263 bile duct) and 959 population controls were enrolled
Abbreviations: BMI, body mass index; CI, conﬁdence interval; INS, insulin;
LD, linkage disequilibrium; OR, odds ratio; PPAR, peroxisome proliferator-
activated receptor; RXR, retinoid X receptor; SNP, single-nucleotide
polymorphism.
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who reviewed histology slides and clinical data from computed tomography
scan, magnetic resonance imaging, abdominal ultrasound or endoscopic retro-
grade cholangiopancretography. An independent review was carried out by
a USA pathologist to further conﬁrm the cancer diagnosis. Biliary stone cases
were selected by frequency matching to cancer cases on age (5-year intervals),
gender and hospital. Population controls were recruited from all permanent
residents listed in the Shanghai Resident Registry. Healthy subjects who did
not have a history of cancer were selected randomly and frequency matched to
the expected age distribution (5-year category) of biliary tract cancer cases. The
participation rates were 95 and 82% among the eligible cancer cases and con-
trols, respectively.
All participants were assessed for their biliary stone status. For biliary
cancer cases, presence of biliary stones was determined using data from clin-
ical diagnostic workup (abdominal ultrasound, computed tomography scan,
endoscopic retrograde cholangiopancretography and magnetic resonance im-
aging), medical record review and in-person interview. Cases were interviewed
within 3 months of their initial cancer diagnosis. Biliary stone status among
population controls was determined based on their self-reported history of
stones or cholecystectomy and abdominal ultrasound results. About 85% of
the controls agreed to ultrasound screening for the detection of stones. The
15% of controls who did not agree to an ultrasound were also included in the
study since it was estimated that about only 1% of them would have had silent
gallstones.
Data collection
Information on potential risk factors was elicited through an in-person inter-
view by trained interviewers, using a structured questionnaire. The interview
included information on demographic characteristics, occupation, dietary his-
tory, smoking history, consumption of alcohol and other beverages, reproduc-
tive factors, medical history, family history of cancer, physical activity and
body size. Subjects were measured for current weight, waist and hip circum-
ferences and height at the interview. All measurements were taken by trained
interviewers, using a standard protocol. The response rate for interviews was
.95% among cases and 82% among controls. Five percent of the study sub-
jects were randomly selected for reinterview 3 months after the initial inter-
view to assess the reproducibility of responses. The concordance of responses
to key questions between the original and follow-up interviews was .90%.
Blood collection and DNA extraction
Overnight fasting blood samples were collected from subjects who gave con-
sent. The blood samples were collected in Vacutainer tubes containing ethyl-
enediaminetetraacetic acid or heparin and processed within 4 hours of
collection at a central laboratory at Shanghai Cancer Institute and stored at
 70C. The frozen buffy coat samples (separated from 5 ml of blood) were
shipped to USA on dry ice. Genomic DNAwas extracted from buffy coat using
phenol–chloroform with a standard protocol. Genotyping for all seven single-
nucleotide polymorphisms (SNPs) [PPAR-c (exon 6, C161T, rs3856806),
PPAR-d (exon 4, T15C, rs2016520), RXR-a (intron 7, G70A, rs1536475 and
intron 8, A-27G, rs1805343),RXR-b (exon 10, G392T, rs2744537and intron 3,
C51T, rs2076310) and INS (intron 1, A-6T, rs689)] were performed using
TaqMan assay (Applied Biosystems, Foster City, CA) at the National Cancer
Institute Core Genotyping Facility (Gaithersburg, MD). These polymorphisms
were selected a priori based on two criteria: (i) having either a reported prev-
alence of at least 5% for the variant allele among Asians and reported evidence
of an association with disease (particularly cancer) and (ii) availability of
a validated assay at the Core Genotyping Facility. All assays were validated
and optimized at the Core Genotyping Facility laboratory. Speciﬁc primers,
probes and methods used to detect polymorphisms are publicly available at
http://snp500cancer.nci.nih.gov/ (27). Coriell DNA samples containing homo-
zygous major allele, heterozygous and homozygous minor allele genotype
were used as internal laboratory quality control for each polymorphism stud-
ied, including four of each type and four no-template controls per plate (384
samples). DNA samples for cases and controls were grouped into pairs to
minimize the effect of day-to-day laboratory variation. Laboratory personnel
were blinded to the identity of subjects. A total of 80 quality control samples
from four individuals were placed along with study samples to estimate the
reproducibility of genotyping assays. The concordance was .99%.
Statistical analysis
This study included all subjects who consented to provide blood and for whom
we had genotype data: 411 biliary tract cancer cases (237 gallbladder, 127 bile
duct and 47 ampulla of Vater), 895 biliary stone cases (673 gallbladder and 222
bile duct) and 786 population controls. All statistical analyses were conducted
using SAS version 8.2 (SAS Institute, Cary, NC). Baseline characteristics of
cases and controls were compared using the chi-square test. Asymptotic Pear-
son’s chi-square test was used to test Hardy–Weinberg equilibrium for geno-
typefrequencies forall the SNPs amongpopulationcontrols in this study. Odds
ratios (ORs) for biliary tract cancer and biliary stone risk and 95% conﬁdence
intervals (CIs) were calculated using unconditional logistic regression. For the
entire analyses, gallbladder cancer cases were compared with population con-
trols who did not have a cholecystectomy (n 5 737), bile duct and ampullary
cancer cases were compared with all population controls (n 5 786) and biliary
stone cases (gallstone or bile duct stone) were compared with the subset of
population controls without any type of stone (n 5 592). An initial model was
adjusted for age and additional models were further adjusted for gender, body
Table I. Selected characteristics of subjects by case–control status
Selected characteristics Population control
a Biliary tract cancers Biliary stones
N1
(n 5 786)
N2
(n 5 737)
N3
(n 5 592)
Gallbladder
(n 5 237)
Bile duct
(n 5 127)
Ampulla of Vater
(n 5 47)
Gallbladder
(n 5 673)
Bile duct
(n 5 222)
Gender (%)
Male 38.8 39.4 42.6 27.4
b 59.8
b 51.1 33.3
b 47.3
Female 61.2 60.6 57.4 72.6 40.2 48.9 66.7 52.7
Age at interview (%)
,55 14.3 15.1 17.1 14.0 15.1 8.7 33.8
b 24.5
b
55–64 24.8 25.7 25.4 23.6 20.2 17.4 23.9 27.8
 65 60.9 59.2 57.5 62.4 64.7 73.9 42.3 47.7
Education (%)
None/primary 40.2 39.1 37.7 53.2
b 41.7 46.8 28.7
b 35.1
Middle/high school 44.7 45.9 46.5 37.5 44.1 42.6 53.6 49.1
College or above 15.1 15.1 15.9 9.3 14.2 10.6 17.7 15.8
BMI (kg/m2) (%)
,18.5 8.4 8.8 9.3 4.7
b 4.7 2.1 3.7
b 6.8
b
18.5–22.9 41.4 42.5 45.4 33.5 44.9 42.6 34.1 33.3
23–24.9 21.2 21.1 20.8 19.9 26.0 53.4 24.4 23.0
 25 29.0 27.6 24.5 42.0 24.4 31.9 37.8 36.9
History of hypertension (%) 42.8 41.9 40.0 36.7 29.1
b 27.7
b 34.0
b 28.8
b
History of diabetes (%) 8.3 7.6 6.4 13.1
b 9.5 6.4 11.1
b 11.3
b
Cigarette use (%) 30.1 30.3 31.6 27.1 44.1
b 42.5 23.9
b 36.0
Alcohol use (%) 20.6 20.5 22.6 15.2 33.1
b 25.5 15.0
b 18.5
aN1, all controls; N2, controls without cholecystectomy; N3, controls without biliary stone.
bP value ,0.05 for comparison between cases and controls.
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and gallstone status (cancer risk only) in order to evaluate the potential con-
founding by these factors. To evaluate effect modiﬁcation, stratum-speciﬁc
risks were examined for each of the above-mentioned factors, and multiplica-
tiveinteraction terms were added to the age-adjusted model.For thegenes with
more than one SNP examined in our study, a corrected P value of the overall
association between polymorphisms and each outcome of interest was derived
to further takeinto accountthe potentialproblem ofmultiplecomparisons(28).
In addition, we calculated the false positive reporting probability in order to
assess the likelihood of having false-positive ﬁndings (29).
Results
Selected characteristics of cases and controls are shown in Table I.
More women were diagnosed with gallstones and gallbladder cancer,
whereas more men were diagnosed with bile duct cancer. Compared
with controls, biliary stone and gallbladder cancer cases had a higher
BMI and were more likely to have a history of diabetes. Bile duct
cancer cases were more likely to smoke cigarettes and drink alcohol,
whereas gallstone cases were less likely to smoke and drink alcohol
than controls. Biliary tract cancer and biliary stone cases were less
likely to have a history of hypertension than controls.
The age-adjusted ORs and 95% CI for biliary tract cancer and
biliary stones in relation to seven variants are shown in Table II.
Among controls, all SNPs were in Hardy–Weinberg equilibrium. Be-
cause two variants, RXR-b G392Tand INS A-6T, had a low frequency
of homozygous variant genotypes and PPAR-d T15C did not have
a homozygous variant genotype for ampulla of Vater cancer cases,
we combined the homozygous and the heterozygous variant geno-
types. Overall, there was no signiﬁcant association between these
seven variants and the risk of bilairy tract cancer and stones, although
the homozygous genetic variant (TT) of the RXR-b C51T marker
was marginally associated with an increased risk of bile duct cancer
(OR 5 1.67; 95% CI 5 0.99–2.84). Among population controls, the
frequency of the variant TT genotype of the RXR-b C51T marker was
12%, which is slightly less than the frequency of 17% among the 72
Asian/Paciﬁc Rim subjects reported in SNP500 (http://snp500cancer.
nci.nih.gov) (27).
The effect of the RXR-b C51T marker on bile duct cancer was
limited to men (Table III). Among men, those with the TT genotype
of the RXR-b C51T marker had a 2.3-fold risk of bile duct cancer
(95% CI 5 1.14–4.65; P adjusted for multiple comparisons 5 0.04),
whereas female carriers did not have an excess risk (P interaction 5
0.07). Further adjustment for gallstones did not materially change the
results (OR 5 2.45; 95% CI 5 1.11–5.38). In addition, among sub-
jects with a higher BMI ( 23 kg/m2), those carrying the TT genotype
of the RXR-b C51T marker had a 1.8-fold risk of gallstones (95%
CI 5 1.09–2.94; P adjusted for multiple comparisons 5 0.04), but
not among those with a lower BMI (,23 kg/m2) (OR 5 0.70; 95%
CI 5 0.38–1.31) (P interaction 5 0.28). These ﬁndings for the RXR-
b C51T marker among men and those with a high BMI were
Table II. ORs and 95% CIs for biliary tract cancers and stones in relation to selected genetic variants
Gene/variants Controls
a Biliary tract cancers Biliary stones
Gallbladder
(n 5 237)
Bile duct
(n 5 127)
Ampulla of Vater
(n 5 47)
Gallbladder
(n 5 673)
Bile duct
(n 5 222
N1 N2 N3 n OR (95% CI) n OR (95% CI) n OR (95% CI) n OR (95% CI) n OR (95% CI)
RXR-a G70A (rs1536475)
GG 443 414 334 135 1.00 74 1.00 27 1.00 385 1.00 123 1.00
GA 282 266 212 90 1.04 (0.76–1.42) 44 0.93 (0.62–1.39) 16 0.93 (0.49–1.76) 234 0.92 (0.72–1.17) 78 1.02 (0.73–1.43)
AA 51 47 37 10 0.65 (0.32–1.33) 6 0.71 (0.29–1.71) 3 — 43 0.91 (0.57–1.46) 14 0.99 (0.51–1.90)
P for trend 0.55 0.46 0.89 0.49 0.95
RXR-a A-27G (rs1805343)
AA 317 298 239 98 1.00 51 1.00 21 1.00 268 1.00 94 1.00
GA 351 329 266 107 1.00 (0.73–1.37) 53 0.94 (0.62–1.43) 21 0.93 (0.50–1.73) 307 0.98 (0.77–1.26) 94 0.89 (0.64–1.25)
GG 105 98 76 26 0.80 (0.49–1.31) 21 1.25 (0.72–2.17) 4 — 84 0.91 (0.63–1.31) 26 0.87 (0.53–1.45)
P for trend 0.50 0.60 0.39 0.66 0.48
RXR-b G392T (rs2744537)
GG 720 676 539 221 1.00 118 1.00 44 1.00 603 1.00 199 1.00
TG þ TT
b 56 52 45 14 0.82 (0.45–1.52) 7 0.76 (0.34–1.72) 2 — 59 1.21 (0.80–1.82) 17 1.01 (0.56–1.81)
P for trend 0.53 0.51 — 0.37 0.98
RXR-b C51T (rs2076310)
CC 331 303 234 97 1.00 53 1.00 22 1.00 255 1.00 93 1.00
TC 353 339 284 101 0.94 (0.68–1.29) 47 0.84 (0.55–1.27) 21 0.92 (0.50–1.71) 313 0.98 (0.77–1.25) 92 0.82 (0.58–1.14)
TT 93 86 67 36 1.30 (0.83–2.04) 25 1.67 (0.99–2.84) 3 0.47 (0.14–1.60) 94 1.28 (0.89–1.85) 32 1.20 (0.74–1.95)
P for trend 0.46 0.21 0.29 0.34 0.94
INS A–6T (rs689)
AA 698 658 528 214 1.00 116 1.00 43 1.00 603 1.00 200 1.00
TA þTT
b 73 65 52 20 0.96 (0.57–1.62) 7 0.57 (0.26–1.99) 3 — 57 0.96 (0.64–1.44) 15 0.79(0.43–1.44)
P for trend 0.88 0.18 — 0.85 0.44
PPAR-c C161T (rs3856806)
CC 457 428 350 127 1.00 74 1.00 27 1.00 411 1.00 135 1.00
TC 284 264 205 95 1.22 (0.89–1.65) 44 0.96 (0.64–1.43) 18 1.10 (0.60–2.04) 226 0.92 (0.72–1.17) 69 0.86 (0.62–1.21)
TT 41 41 34 15 1.25 (0.67–2.33) 8 1.21 (0.55–2.69) 2 — 35 0.84 (0.51–1.39) 17 1.26 (0.68–2.34)
P for trend 0.21 0.88 0.93 0.36 0.97
PPAR-d T15C (rs2016520)
TT 388 362 286 119 1.00 65 1.00 26 1.00 311 1.00 114 1.00
TC 267 253 209 81 0.98 (0.71–1.36) 42 0.95 (0.63–1.45) 16 0.76 (0.40–1.44)
b 224 0.96 (0.75–1.24) 77 0.89 (0.63–1.26)
CC 60 56 42 20 1.09 (0.63–1.89) 10 1.00 (0.49–2.06) 66 1.36 (0.89–2.08) 12 0.72 (0.36–1.42)
P for trend 0.87 0.90 0.14 0.40 0.29
aBile duct cancer and ampullary cancer cases were compared with all population controls (N1), gallbladder cancer cases were compared with controls without
cholecytectomy (N2), and gallbladder and bile duct stone were compared with controls without biliary stones (N3).
bOR was calculated for homozygous and heterozygous variants combined due to rare homozygous variant carrier.
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ing a prior probability of association of 0.1.
Discussion
In this population-based case–control study, we found that the TT
genotype of the RXR-b C51T marker was associated with a 2.3-fold
risk of bile duct cancer in men and a 1.8-fold risk of gallstones among
subjects with a BMI .23 kg/m2. No association was found for the
other SNPs examined in the study.
The observed effect of the RXR-b variant in bile duct cancer among
men, independent of gallstones, suggests that RXRs may affect the
risk of bile duct cancer through mechanisms other than gallstones.
Since RXR-b gene variants may change the expression or function of
PPAR/RXR heterodimers (13), which in turn can affect insulin sen-
sitization (15,16), it is possible that RXR-b variants can affect the risk
of bile duct cancer through insulin resistance or inﬂammation. It is
unclear as to why the association between the RXR-b C51T marker
and bile duct cancer was limited to men. Since this association per-
sisted after further adjustment for additional variables, confounding
by factors such as smoking and alcohol drinking, which are predom-
inant among men in this study population, should be minimal. Thus,
our ﬁnding suggests a gender-speciﬁc role of RXR-b through mech-
anisms other than smoking and alcohol drinking. However, it is im-
portant to note that we had considerably fewer women than men with
bile duct cancer, which may have limited our statistical power to
observe a genetic association among women.
The observation that carriers of the RXR-b TT genotype with a high
BMI ( 23 kg/m2) had an excess risk of gallstones is not surprising,
since both obesity and diabetes, conditions closely related to insulin
resistance, are important risk factors for gallstones (5,6,30–34). RXR-
b can form heterodimers with PPARs to regulate the transcription of
various genes implicated in insulin sensitization, thus it is possible
that RXR-b can affect gallstone risk through regulation of insulin
resistance (15,16). In some studies, the effect of insulin resistance
on gallstones persisted after adjustment for obesity (32–34), suggest-
ing that insulin resistance may play a role in the etiology of gallstones
independent of obesity (35).
It is also possible that RXR-b may affect the risk of bile duct cancer
or gallstones through other unknown causal genes that are in linkage
disequilibrium (LD) with the RXR-b variant. For example, previous
studies have reported that the RXR-b gene is localized in the major
histocompatibility complex class II region between the DPB1 and
RING2 genes (36). Signiﬁcant LD between certain RXR-b alleles
and HLA-DPB1 alleles has been described (37); however, whether
the RXR-b C51T has a LD with HLA-DPB1 alleles warrants further
study.
Strengths of our study should be noted. This is the ﬁrst large pop-
ulation-based study to investigate genetic variants related to insulin
sensitivity in relation to biliary tract cancer and biliary stones. The
population-based design and high response rate of participants mini-
mized the potential for selection bias. Because cancer diagnoses were
conﬁrmed by careful review of pathological records and case ascer-
tainment was .95%, potential selection misclassiﬁcation was also
minimal. In addition, simultaneously investigating both biliary tract
cancer and biliary stones allowed us to further examine whether risks
associated with various exposures, including genetic susceptibility,
are similar between these two closely related outcomes.
Despite being the largest case–control study of biliary tract cancer
to date, we had limited statistical power to evaluate main effects of
ampulla of Vater cancer and the effect of gene–environment or gene–
gene interactions due to low allele frequency and the small number of
bile duct and ampullary cancer cases. Because our study was con-
ducted within a fairly homogeneous Chinese population, we had lim-
ited generalizability. A major limitation of our study is incomplete
gene coverage since we included only seven SNPs in this pathway.
Table III. ORs and 95% CI for biliary tract cancers and stones in relation to RXR-b C/T polymorphism, a stratiﬁcation of gender and BMI
RXR-b C/T Population control
a Biliary tract cancers Biliary stones
Gallbladder
(n 5 237)
Bile duct
(n 5 127)
Ampulla of Vater
(n 5 47)
Gallbladder stones
(n 5 673)
Bile duct stones
(n 5 222)
N1 N2 N3 n OR (95% CI) n OR (95% CI) n OR (95% CI) n OR (95% CI) n OR (95% CI)
Male
CC 126 115 96 30 1.0 27 1.0 10 1.0 83 1.0 42 1.0
CT 140 138 123 26 0.73 (0.41–1.32) 30 1.01 (0.57–1.80) 13 1.24 (0.52–2.96) 108 0.97 (0.65–1.45) 45 0.80 (0.48–1.32)
TT 36 34 31 9 0.99 (0.43–2.30) 18 2.30 (1.14–4.65)
b 0 — 29 1.01 (0.56–1.83) 16 1.13 (0.55–2.30)
P for trend 0.65 0.05 0.34 0.97 0.94
Female
CC 205 188 138 67 1.0 26 1.0 12 1.0 172 1.0 51 1.0
CT 213 201 161 75 1.06 (0.85–1.57) 17 0.62 (0.33–1.18) 8 0.63 (0.25–1.58) 205 1.01 (0.74–1.38) 47 0.82 (0.52–1.29)
TT 57 52 36 27 1.47 (0.45–2.54) 7 0.94 (0.39–2.29) 3 — 65 1.53 (0.95–2.46) 16 1.24 (0.63–2.44)
P for trend 0.22 0.46 0.51 0.16 0.92
P interaction 0.30 0.07 0.80 0.91 0.34
BMI , 23 kg/m2
CC 145 139 113 37 1.0 26 1.0 14 1.0 100 1.0 37 1.0
CT 193 188 167 38 0.76 (0.46–1.25) 21 0.61 (0.33–1.13) 7 0.39 (0.15–0.99)
c 124 0.81 (0.56–1.17) 39 0.72 (0.43–1.21)
TT 45 43 36 15 1.29 (0.65–2.58) 16 1.99 (0.97–4.05) 0 — 23 0.70 (0.38–1.31) 12 1.10 (0.51–2.38)
P for trend 0.88 0.008 0.17 0.72
BMI   23 kg/m2
CC 186 164 121 60 1.0 27 1.0 8 1.0 155 1.0 56 1.0
CT 160 151 117 62 1.14 (0.75–1.73) 26 1.13 (0.63–2.01) 14 2.07 (0.85–5.07) 188 1.22 (0.87–1.71) 53 0.98 (0.62–1.55)
TT 47 42 30 21 1.38 (0.75–2.51) 9 1.32 (0.58–3.00) 3 — 71 1.80 (1.09–2.94)
d 20 1.40 (0.73–2.69)
P for trend 0.29 0.50 0.28 0.02 0.45
P interaction 0.18 0.88 0.05 0.28 0.12
aBile duct cancer and ampullary cancer cases were compared with all population controls (N1), gallbladder cancer cases were compared with controls without
cholecystectomy (N2) and gallbladder and bile duct stone were compared with controls without biliary stones (N3).
bP value corrected for multiple comparison 5 0.04.
cP value corrected for multiple comparison 5 0.10.
dP value corrected for multiple comparison 5 0.04.
Polymorphism of genes related to insulin sensitivity
947Thus, we may have missed the effect of some important markers, and
our ﬁndings may actually represent markers for other functional SNPs
that are in LD.
In summary, in this population-based study, we found that RXR-b
gene variants are associated with bile duct cancer in men and to
gallbladder stones among subjects with a higher BMI. Further studies
with greater statistical power and broader coverage of the RXR-b gene
are needed to conﬁrm our ﬁndings and identify causal gene variants.
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